# A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

> **NCT04385563** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 338 (estimated)

## Conditions studied

- HER2-positive Metastatic Breast Cancer

## Interventions

- **DRUG:** TQ-B211
- **DRUG:** Herceptin®
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT04385563
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-11
- **Primary completion:** 2021-02
- **Final completion:** 2021-10
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04385563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04385563, "A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04385563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*